INNOVADERM CRO IS NOW INDERO.

The Dual-Focus CRO For
Dermatology & Rheumatology

We’re Indero. A clinical trial delivery partner for immune-mediated diseases. Every therapy deserves a champion. Meet yours.

circle_bg_out.png
circle_bg_out.png

Is Now

For over two decades, Innovaderm has been the leading dermatology CRO and one of the largest dermatology Clinical Research Units (CRU) in North America. As we continue to grow and support immune-mediated diseases—including those in rheumatology, a therapeutic area inextricably linked to dermatology—we have rebranded the CRO side of our business to Indero. Our CRU will retain the name Innovaderm and will continue to conduct dermatology studies.

Clinical Trial Delivery.

Beginning to End

Indero offers clinical trial delivery solutions for dermatology and rheumatology, covering both early and late phase trials. Our integrated and targeted services span the world, with capabilities in North America, Europe, Latin America, and Asia-Pacific. Leveraging our relationships with investigators globally, we excel in addressing the unmet needs of immune-mediated disease studies worldwide.

Our Therapeutic Expertise

Indero’s dual-focus, interdisciplinary approach allows us to support clinical studies for a wide range of dermatology and rheumatology conditions.

A Global Clinical Leader in Dermatology

Formerly known as Innovaderm, Indero is a world-renowned expert and clinical research leader in dermatology. We have more than two decades of experience serving a broad range of indications, patient populations, administration routes, and drug classes, and a global footprint.

25+

 Years of Experience

500+

Clinical Trials

3,100+

Investigators

30+

Indications

Examples of dermatology indications we specialize in: ​

  • Atopic dermatitis

  • Psoriasis

  • Alopecia areata

  • Hidradenitis suppurativa

  • Chronic inducible urticaria

  • Chronic spontaneous urticaria

  • Vitiligo

  • Acne

  • Rosacea

  • Chronic hand eczema

  • Notalgia paresthetica

  • Actinic keratosis

  • GPP, PPP and PPPP

  • Hyperhidrosis

  • Prurigo nodularis

  • Onychomycosis

  • Cosmetics and aesthetics

Every Therapy Deserves a Champion. Meet Yours.

Indero brings 25+ years’ experience in clinical research and trial delivery. Our full-service, value-added approach provides biotech and pharmaceutical sponsors with the rigorous scientific foundation and tailored expertise their studies need to reach the finish line.

Recent Insights

Innovaderm to Indero
Podcast

Episode 35: PTCA – Speaking the Same Language: How Patient Organizations and Sponsors Can Align in Clinical Trials

News

Indero Announces Breakthrough Method for Early-Phase Evaluation of Topical Drugs Using Quantitative Gene Expression

Case Study

Urticaria Case Study

Wherever
You’re Going,
We’re all in.

Need help with your next study? We want to learn more. Fill out the form on the right and one of our experts will be in touch.

Jeff Smith

Chef de la direction

Jeff Smith, Chef de la direction d’Indero Recherches, apporte prĂšs de 30 ans d’expĂ©rience dans l’industrie pharmaceutique et CRO, s’Ă©tant distinguĂ© par son leadership exceptionnel, sa vision stratĂ©gique et son innovation. L’expertise de Jeff couvre des opĂ©rations mondiales, la gestion de la croissance, ainsi que la promotion d’une culture d’entreprise collaborative. Ses atouts en matiĂšre de crĂ©ation de valeur, de gestion des partenaires et d’opĂ©rations CRO ont toujours contribuĂ© au succĂšs dans ses fonctions prĂ©cĂ©dentes. Sous la direction de Jeff, Indero continue d’étendre ses capacitĂ©s, faisant progresser les connaissances mĂ©dicales et les nouvelles thĂ©rapies en dermatologie et en rhumatologie.

Revolutionize Your Topical Trials

Efficacy insights in days, not months.

 Indero’s Early Phase 1 model enables sponsors to initiate topical studies that detect early pharmacodynamic signals much sooner than traditional phase 1, using microdosing and transcriptomic analysis. This approach reduces preclinical requirements, shortens study duration from 8–12 weeks to ≀3 days, and lowers costs, helping teams make informed go/no-go decisions faster.